

# p16 Immunohistochemical Expression in Nephrogenic Adenoma

Juan Carlos Alvarez Moreno <sup>1</sup>, Hafiz A. Ghani <sup>1</sup>, Vasily Ovechko <sup>1</sup>, Cecilia Clement <sup>1</sup>, Eduardo Eyzaguirre <sup>1</sup>

1. Pathology, University of Texas Medical Branch at Galveston, Galveston, USA

**Corresponding author:** Juan Carlos Alvarez Moreno, juanalvarezmo25@gmail.com

Review began 06/20/2023

Review ended 06/30/2023

Published 07/02/2023

© Copyright 2023

Alvarez Moreno et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

Nephrogenic adenoma (NA) is a rare metaplastic entity commonly associated with a prior urothelial injury. Most are seen in the urinary bladder and a minority involve the urethra. In this study, we evaluated the expression of p16 as a surrogate marker of this entity and correlated it with clinical pathological parameters. A total of 17 cases of NA were retrospectively studied to assess the immunohistochemical expression of p16 and its value for the diagnosis of this entity.

**Categories:** Pathology, Urology, Oncology

**Keywords:** urothelial carcinoma, clear cell carcinoma, genitourinary tract, p16, nephrogenic adenoma

## Introduction

Nephrogenic adenoma (NA) in the genitourinary tract is a rare metaplastic benign entity [1]. The term was introduced by Friedman and Kuhlbeck because it resembled a renal tubule [2]. Microscopically, it consists of tubules, and papillary fronds lined by cuboidal eosinophilic cells or flat epithelium with hobnail nuclei. Nuclear enlargement with hyperchromasia and prominent nucleoli can be present, although frequently focal and of degenerative nature. These atypical features can cause possible confusion with prostate cancer and with clear cell adenocarcinoma of the urethra [2]. According to the literature, it has been associated with recurrent urinary tract calculi, recurrent urinary tract infections, trauma, prior surgery, diverticula of the urinary bladder, intravesical therapy, kidney transplantation, radiotherapy, foreign bodies, and chemical agents [3]. The most common location is the urinary bladder (80%) and other locations include the urethra (15%), ureter (5%), and rarely the renal pelvis [3].


NA can express PAX8 as a renal transcription factor that is always co-expressed with PAX2 in embryonic and adult renal tissues. These are cell lineage-restricted transcription factors expressed in normal and neoplastic tissues of renal tubular cells in fetal and adult kidneys [4]. The INK4 class are cell cycle inhibitors with a tumor suppressor gene known as p16 (CDKN2A); therefore, p16 overexpression drives cell death and apoptosis [5]. Hence, some non-human papillomavirus (HPV) tumors (melanoma, mesothelioma, liposarcoma, serous carcinoma) can have p16 positive expressions. p16 expression can be seen in metaplastic and atrophic cells of cervical origin [6-7]. HPV expresses high levels of p16 [8]; however, there is no connection between p16 expression by immunohistochemistry and HPV infection [1]. To the best of our knowledge, there are no reports in the literature regarding p16 expression in NA. Here, we explore p16 expression in NA, with attention to clinical and pathologic characteristics, and assess the potential pitfalls associated with the use of this marker.

## Materials And Methods

This retrospective study included 17 patients with NA from the University of Texas Medical Branch (UTMB), Galveston, Texas, United States. The collection period was from 2015 to 2022. We included patients with NA (Figure 1, A and B-1) from different locations, PAX-8 positive to support the diagnosis (Figure 1, B-2), and a p16 immunohistochemical (IHC) stain was performed. For the patients who met the inclusion criteria, their clinical information was redeemed from medical records, including age, HPV status, gender, history of transplant or malignancy, and urolithiasis.

### How to cite this article

Alvarez Moreno J, Ghani H A, Ovechko V, et al. (July 02, 2023) p16 Immunohistochemical Expression in Nephrogenic Adenoma. Cureus 15(7): e41285. DOI 10.7759/cureus.41285



**FIGURE 1: (A) H&E: 20X Papillary fronds lined by cuboidal eosinophilic cells; (B) H&E: 1. 20x Vascular-like tubules lined by cuboidal epithelium, bland round nuclei with inconspicuous nucleoli, with eosinophilic luminal secretions, 2. 20x PAX-8 positive nuclear stain; (C) IHC: p16 en-bloc positive expression with nuclear and cytoplasmic staining; (D) IHC: p16 patchy positive expression with nuclear and/or cytoplasmic staining**

IHC: immunohistochemistry; H&E: hematoxylin and eosin

We took sections from tissue blocks embedded in paraffin and slides were stained with p16 primary antibody (Clone CINtec 16, Ventana). The corresponding hematoxylin & eosin (H&E) slides were analyzed in accordance with their compatible IHC stains. The IHC stain was positive when brown-gold cytoplasmic and/or nuclear staining and negative with no expression. p16 expression was categorized into en-bloc and patchy patterns (Figure 1, C and D).

Results

The clinicopathological features are given in Table 1. The mean age was similar in both groups of p16 pattern. The en bloc pattern had more cases of NA than the patchy pattern. The male population showed slightly more cases of NA, and was predominant in both p16 patterns. A few cases in both groups had a history of bladder cancer. The en bloc pattern group had a higher history of prostate cancer than the patchy pattern group. There were few cases with calculi in both groups. The most common lesion type in the en bloc pattern group was erythema, while in the patchy pattern group were polyps. The patchy pattern group showed more cases being single lesions rather than multiple compared to the en bloc group. Cystourethroscopy was the most common procedure in both groups. The most common location identified in both groups was lateral in the bladder as well as posterior for the patchy group. Only one HPV-positive case was present in each group.

Clinicopathological Factors	En bloc (n=10)	Patchy (n=7)
Age (years, mean ± standard deviation)	57.1 ± 17.5	58.9 ± 18.9

Gender, n(%)		
Female	4 (40.0)	2 (28.6)
Male	6 (60.0)	5 (71.4)
History of bladder cancer, n(%)		
No	9 (90.0)	5 (71.4)
Yes	1 (10.0)	2 (28.6)
History of prostate cancer, n(%)		
No	1 (10.0)	3 (42.8)
Yes	8 (80.0)	2 (28.6)
Not applicable	1 (10.0)	2 (28.6)
Calculi, n(%)		
No	8 (80.0)	5 (71.4)
Yes	2 (20.0)	2 (28.6)
Lesion type, n(%)		
Polyp	1 (10.0)	3 (42.8)
Erythema	3 (30.0)	2 (28.6)
Sessile	1 (10.0)	2 (28.6)
Papillary	2 (20.0)	0 (0.0)
Stricture	1 (10.0)	0 (0.0)
Diverticulum	1 (10.0)	0 (0.0)
No data	1 (10.0)	0 (0.0)
Number of lesions, n(%)		
Single	4 (40.0)	6 (85.7)
Multiple	3 (30.0)	1 (14.3)
No data	3 (30.0)	0 (0.0)
Location, n(%)		
Bladder, lateral	3 (30.0)	3 (42.8)
Bladder, posterior	0 (0.0)	4 (57.2)
Bladder, other	5 (50.0)	0 (0.0)
Prostate	1 (10.0)	0 (0.0)
Urethra	1 (10.0)	0 (0.0)
Procedure, n(%)		
Cystourethroscopy	6 (60.0)	6 (85.7)
Transurethral resection of prostate	1 (10.0)	1 (14.3)
Transurethral resection of bladder tumor	2 (20.0)	0 (0.0)
Hysterectomy	1 (10.0)	0 (0.0)
HPV status, n(%)		
Positive	1 (10.0)	1 (14.3)
Negative	2 (20.0)	0 (0.0)
No data	7 (70.0)	6 (85.7)

TABLE 1: Clinicopathological Factors

HPV: human papillomavirus

Discussion

We found that p16 nuclear and cytoplasmic expression was positive in all NA cases. The pattern distribution in 10 cases was en bloc and in seven cases was patchy. In a study by Tringler et al p16 positivity in the uterine cervix was seen in 6.5% of normal squamous mucosa, 37.5% in ciliated columnar cells of endocervical glands, 30% of Nabothian cysts, and 100% in tubal metaplasia [9]. In the oropharynx, there is evidence of focal p16 expression in benign tonsillar tissue, nondysplastic squamous epithelium, tumor stroma, and benign papillomas [10,11]. Most of these cases showed a mosaic pattern of distribution rather than en bloc. Our study is the first to acknowledge this pattern of expression. In anogenital lesions, the p16 protein expression should be nuclear or nuclear and cytoplasmic when associated with HPV [12]. Our cohort showed both patterns as previously mentioned.

NAs can present as irritative voiding symptoms and the usual complaint is hematuria [13]. Imaging can show polypoid or sessile masses within the bladder with a very nonspecific appearance [14]. Gross examination can reveal papillary, polypod, fungating, or sessile lesions [15]. As mentioned previously, they can have cysts, tubule formation, and solid and papillary growth [16]. Tubules are surrounded by thickened hyalinized membranes and lined by hobnail, cuboidal, or low columnar cells [16]. Their IHC profile shows positive stains for PAX8, BerEP4, and S100A1, and negative for PSA, CEA, and P63 [16].

The main differential diagnosis for this entity is clear cell carcinoma (Table 2). They can also present with hematuria, dysuria, urinary urgency, and recurrent UTIs. They can have NA hobnailed nuclei, vascular-like tubules with attenuated epithelium, and eosinophilic cells with different architectural patterns of growth, such as papillary, tubulocystic, or solid [17]. The most predominant features are clear cells, necrosis, severe atypia, high Ki-67, and mitotic rate [17]. By imaging, they can present as hydronephrosis or hydroureter, and grossly they present as solid, papillary, sessile, polypoid, and fungating lesions like NAs [17]. They can also be positive for cytokeratins (CK20, CK7), CEA, Napsin A, PAX8, and CA125 and CD10 is negative in these tumors [17]. In clear cell carcinomas, p16 can show a diffuse pattern [17]. This falls into the pitfall with nephrogenic adenomas with our current results.

	Nephrogenic Adenoma	Clear Cell Carcinoma
Symptoms	Palpable mass, recurrent UTIs, obstructive urinary symptoms, hematuria	Hematuria, dysuria, obstructive urinary symptoms, recurrent UTIs
Imaging	Solid or sessile masses	Solid mass, hydronephrosis, or hydroureter
Gross appearance	Solid, sessile, papillary, fungating	Solid, papillary, sessile, polypoid, fungating
Nuclear atypia	Rare	Common
Histological features	Tubules surrounded by hyalinized basement membrane	Tubulocystic pattern with hobnail and clear cells
Immunohistochemistry	Positive PAX8, S100A1, BerEP4/EpCAM, Negative P63, PSA, CEA	Positive CK7, CK20, CA125, CEA; Negative CD10

TABLE 2: Differential Diagnosis between Nephrogenic Adenoma and Clear Cell Carcinoma

CK: cytokeratin; CEA: carcinoembryogenic antigen; CD10: cluster of differentiation 10; P63: tumor protein 63; BerEP4/EpCAM: Epithelial Cell Adhesion Molecular; Pax-8: paired box gene 8; UTI: urinary tract infection; PSA: prostatic-specific antigen; CA125: cancer antigen 125

Another entity in the differential is invasive urothelial carcinoma. They present with gross or microscopic hematuria, urinary urgency and frequency, and dysuria [18]. Systemic symptoms can manifest with weight loss, fatigue, bone pain, and metastasis to lymph nodes, liver, lung, and bone [19,20]. The most common location is the bladder (90%) and the upper urinary tract (renal pelvis and/or ureter) accounts for 5-10% [21]. The macroscopic examination can be papillary, sessile, polypoid, nodular, and ulcerative, also unifocal or multifocal [21]. The histologic variants are multiple including conventional, squamous, glandular, trophoblastic, nested, microcystic, micropapillary, lymphoepithelioma-like, plasmacytoid/signet

ring/diffuse, sarcomatoid, giant cell, lipid-rich, clear cell, and poorly differentiated [22]. The IHC markers that support the urothelial lineage are GATA3, p63, and high-molecular-weight cytokeratins [23]. p16 can be positive in these tumors; therefore, it has limited utility in distinguishing between cervical squamous cell carcinoma and primary squamous cell carcinoma of the bladder [24]. In a study by Hashmi et al., they classified the p16 IHC stain as low expression and high expression [25]. The high-expression group showed worse long-term survival.

The third entity in the differential is the prostatic acinar adenocarcinoma. This cancer is asymptomatic and detected by increased levels of serum prostatic-specific antigen (PSA) [26]. It can also be incidental or present with hematuria [27]. The primary diagnostic imaging is transrectal ultrasound and MRI [28]. The most common site of distant metastasis is the bone [29]. These tumors are not clearly visible macroscopically, and when they are, they are firm, solid, and poorly circumscribed [30] and are most commonly located in the peripheral zone [31]. Microscopically, the major criteria are haphazard infiltration, nuclear atypia, and absence of basal cells [32]. You can also have more complex architecture, crowding, cords, and fused and cribriform glands [28]. Minor criteria include amphophilic cytoplasm, nuclear hyperchromasia, luminal amorphous eosinophilic material, and crystalloid and blue mucinous secretions [28]. The IHC stains for basal cell markers are high-molecular-weight cytokeratins like CK5/6 or p63, also for cytoplasmic stains we use AMACR [33]. In a study by Takahara et al., p16 expression was an adverse prognostic marker in high-grade prostatic adenocarcinomas [34].

Our study had limitations. First, the number of patients in our cohort was a small sample size from a single institution; a larger study population is warranted for greater generalizability and significance. Second, there was a lack of HPV testing on the majority of our patients, and could not provide a correlation between HPV and p16 expression. We did not compare a different p16 antibody clone to see a different pattern of expression. Finally, no other reports in the literature are available regarding the expression of p16 antibody in NA; therefore, we could not compare our results to others. It would be of interest for future studies to study the correlation between NA, p16, and HPV status.

## Conclusions

The expression of p16 in nephrogenic adenoma is unique and new to the literature. The differential diagnosis includes clear cell carcinoma, urothelial carcinoma with p16 expression and prostatic adenocarcinoma. The correlation with HPV status is still unknown; therefore, it would be interesting if future studies and investigations did HPV molecular testing on these patients, especially in a bigger population.

## Additional Information

### Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

## References

1. Kuzaka B, Pudelko P, Powala A, Gornicka B, Radziszewski P: Nephrogenic adenoma of the urinary bladder: a report of three cases and a review of the literature. *Ann Transplant*. 2014, 19:153-6. [10.12659/AOT.889441](#)
2. Venyo AK: Nephrogenic adenoma of the urinary bladder: a review of the literature. *Int Sch Res Notices*. 2015, 2015:704982. [10.1155/2015/704982](#)
3. Ford TF, Watson GM, Cameron KM: Adenomatous metaplasia (nephrogenic adenoma) of urothelium. An analysis of 70 cases. *Br J Urol*. 1985, 57:427-33. [10.1111/j.1464-410x.1985.tb06303.x](#)
4. Poleev A, Fickenscher H, Mundlos S, et al.: PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. *Development*. 1992, 116:611-23. [10.1242/dev.116.3.611](#)
5. Mahajan A: Practical issues in the application of p16 immunohistochemistry in diagnostic pathology. *Hum Pathol*. 2016, 51:64-74. [10.1016/j.humpath.2015.12.021](#)
6. Serra S, Chetty R: p16. *J Clin Pathol*. 2018, 71:853-8. [10.1136/jclinpath-2018-205216](#)
7. McLaughlin-Drubin ME, Crum CP, Münger K: Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. *Proc Natl Acad Sci U S A*. 2011, 108:2130-5. [10.1073/pnas.1009933108](#)
8. Takeuchi S, Takahashi A, Motoi N, et al.: Intrinsic cooperation between p16INK4a and p21Waf1/Cip1 in the onset of cellular senescence and tumor suppression in vivo. *Cancer Res*. 2010, 70:9381-90. [10.1158/0008-5472.CAN-10-0801](#)
9. Tringler B, Gup CJ, Singh M, Groshong S, Shroyer AL, Heinz DE, Shroyer KR: Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. *Hum Pathol*. 2004, 35:689-96. [10.1016/j.humpath.2004.02.012](#)
10. Junor E, Kerr G, Oniscu A, Campbell S, Kouzeli I, Gourley C, Cuschieri K: Benefit of chemotherapy as part of



- treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. *Br J Cancer*. 2012, 106:358-65. [10.1038/bjc.2011.542](#)
11. Syrjänen S: Human papillomavirus (HPV) in head and neck cancer. *J Clin Virol*. 2005, 32 Suppl 1:S59-66. [10.1016/j.jcv.2004.11.017](#)
12. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T: Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. *Am J Pathol*. 1998, 153:1741-8. [10.1016/S0002-9440\(10\)65689-1](#)
13. Peeker R, Aldenborg F, Fall M: Nephrogenic adenoma--a study with special reference to clinical presentation. *Br J Urol*. 1997, 80:539-42. [10.1046/j.1464-410x.1997.00418.x](#)
14. Wong-You-Cheong JJ, Woodward PJ, Manning MA, Davis CJ: From the archives of the AFIP: Inflammatory and nonneoplastic bladder masses: radiologic-pathologic correlation. *Radiographics*. 2006, 26:1847-68. [10.1148/rg.266065126](#)
15. Epstein JI, Amin MB, Reuter VE: Nephrogenic adenoma. *Bladder Biopsy Interpretation*. Epstein JI, Amin MB, Reuter VE (ed): Lippincott Williams & Wilkins, Philadelphia, PA; 2004. 171-76.
16. Quinones W, Ziobler A, Yao Y, Bing Z: Immunohistochemical markers for the differential diagnosis of nephrogenic adenomas. *Ann Diagn Pathol*. 2013, 17:41-4. [10.1016/j.anndiagpath.2012.05.003](#)
17. Zannoni GF, Santoro A, Angelico G, et al.: Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases. *Hum Pathol*. 2019, 92:10-7. [10.1016/j.humpath.2019.06.005](#)
18. Barocas DA, Boorjian SA, Alvarez RD, et al.: Microhematuria: AUA/SUFU guideline. *J Urol*. 2020, 204:778-86. [10.1097/JU.0000000000001297](#)
19. van Rhijn BW, Burger M, Lotan Y, et al.: Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. *Eur Urol*. 2009, 56:430-42. [10.1016/j.eururo.2009.06.028](#)
20. Babjuk M, Burger M, Compérat EM, et al.: European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma In situ) - 2019 update. *Eur Urol*. 2019, 76:639-57. [10.1016/j.eururo.2019.08.016](#)
21. Invasive urothelial carcinoma. WHO Classification of Tumours, 5th Edition: Urinary and Male Genital Tumours. International Agency for Research in Cancer, Lyon, France; 2022. 150.
22. Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR, Cheng L: Variants and new entities of bladder cancer. *Histopathology*. 2019, 74:77-96. [10.1111/his.13752](#)
23. Amin MB, Trpkov K, Lopez-Beltran A, Grignon D: Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. *Am J Surg Pathol*. 2014, 38:e20-34. [10.1097/PAS.0000000000000240](#)
24. Epstein JI, Egevad L, Humphrey PA, Montironi R: Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. *Am J Surg Pathol*. 2014, 38:e6-e19. [10.1097/PAS.0000000000000238](#)
25. Hashmi AA, Hussain ZF, Irfan M, et al.: Prognostic significance of p16 immunohistochemical expression in urothelial carcinoma. *Surg Exp Pathol*. 2019, 2:3. [10.1186/s42047-019-0030-2](#)
26. Knipper S, Pecoraro A, Palumbo C, et al.: The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. *Cancer Causes Control*. 2020, 31:283-90. [10.1007/s10552-020-01273-5](#)
27. Summerton N, Mann S, Rigby AS, Ashley J, Palmer S, Hetherington JW: Patients with new onset haematuria: assessing the discriminant value of clinical information in relation to urological malignancies. *Br J Gen Pract*. 2002, 52:284-9.
28. Prostatic acinar adenocarcinoma. WHO Classification of Tumours, 5th Edition: Urinary and Male Genital Tumours. International Agency for Research in Cancer, Lyon, France; 2022. 203.
29. Huang JF, Shen J, Li X, et al.: Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. *Ann Transl Med*. 2020, 8:482. [10.21037/atm.2020.03.55](#)
30. Lindh C, Delahunt B, Egevad L: Macroscopic features of prostate cancer. *Pathology*. 2018, 50:382-8. [10.1016/j.pathol.2018.01.002](#)
31. Iremashvili V, Pelaez L, Jordá M, Manoharan M, Rosenberg DL, Soloway MS: Prostate cancers of different zonal origin: clinicopathological characteristics and biochemical outcome after radical prostatectomy. *Urology*. 2012, 80:1063-9. [10.1016/j.urology.2012.08.012](#)
32. Humphrey PA: Diagnosis of adenocarcinoma in prostate needle biopsy tissue. *J Clin Pathol*. 2007, 60:35-42. [10.1136/jcp.2005.036442](#)
33. Magi-Galluzzi C: Prostate cancer: diagnostic criteria and role of immunohistochemistry. *Mod Pathol*. 2018, 31:S12-21. [10.1038/modpathol.2017.139](#)
34. Takahara T, Satou A, Sugie M, Watanabe M, Kanao K, Sumitomo M, Tsuzuki T: Prognostic significance of p16 expression in high-grade prostate adenocarcinoma. *Pathol Int*. 2020, 70:743-51. [10.1111/pin.12997](#)